세계의 에피디올렉스(칸나비디올) 시장 보고서(2025년)

Epidiolex is a prescribed medication containing cannabidiol (CBD), a compound derived from the cannabis plant. It is mainly used to treat two rare and severe forms of epilepsy-Lennox-Gastaut syndrome (LGS) and Dravet syndrome-in patients aged 1 year and older. Epidiolex helps reduce the frequency and severity of seizures by interacting with the endocannabinoid system, although its exact mechanism of action is not completely understood.

The main forms of Epidiolex (cannabidiol) include oral solutions, capsules, and oil solutions. The oral solution is a liquid form of medication taken by mouth, often preferred for pediatric patients or individuals who have difficulty swallowing pills. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used for the treatment of epilepsy, Dravet syndrome, Lennox-Gastaut syndrome, and seizure management.

The epidiolex (cannabidiol) market research report is one of a series of new reports from The Business Research Company that provides epidiolex (cannabidiol) market statistics, including epidiolex (cannabidiol) industry global market size, regional shares, competitors with a epidiolex (cannabidiol) market share, detailed epidiolex (cannabidiol) market segments, market trends and opportunities, and any further data you may need to thrive in the epidiolex (cannabidiol) industry. This epidiolex (cannabidiol) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epidiolex (cannabidiol) market size has grown strongly in recent years. It will grow from $3.55 billion in 2024 to $3.89 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be attributed to an increased focus on patient-centric medical treatments, growing research supporting cannabidiol's effectiveness in treating epilepsy, rising patient awareness of cannabidiol's therapeutic potential, a growing demand for alternative treatments to traditional anti-epileptic drugs, and the expanding global demand for medical cannabis products.

The epidiolex (cannabidiol) market size is expected to see strong growth in the next few years. It will grow to $5.55 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The expected growth in the forecast period is driven by factors such as an increase in insurance companies covering Epidiolex, heightened awareness of the side effects of traditional anti-epileptic medications, growing demand for natural, plant-based medicines, a rising number of children and adults diagnosed with epilepsy, and supportive government policies and frameworks for medical cannabis. Key trends in this period include the integration of cannabidiol into established treatment protocols, advancements in manufacturing technologies, partnerships with healthcare organizations, the inclusion of Epidiolex in treatment plans for intractable epilepsy, the use of artificial intelligence in cannabidiol product development, and the development of water-soluble cannabidiol to enhance bioavailability.

The rising prevalence of epilepsy is expected to drive the growth of the Epidiolex (cannabidiol) market. Epilepsy is a neurological disorder characterized by frequent, unprovoked seizures caused by abnormal electrical activity in the brain. The increasing number of epilepsy cases can be attributed to factors such as improved diagnosis, greater awareness, and the growing incidence of conditions such as brain injuries, stroke, and genetic factors. Epidiolex, a prescription medication derived from cannabidiol (CBD), is used to treat certain types of epilepsy by reducing the frequency and severity of seizures through modulation of the brain's signaling pathways. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 2.9 million U.S. adults aged 18 and older had active epilepsy in 2022, representing about 1% of the adult population. Additionally, around 456,000 children under 18 in the U.S. were estimated to have active epilepsy. As such, the growing prevalence of epilepsy is driving the demand for Epidiolex (cannabidiol).

Companies in the Epidiolex (cannabidiol) market are focusing on developing innovative products, such as synthetic cannabidiol (CBD) formulations, to gain a competitive advantage. A synthetic cannabidiol product is a lab-created version of CBD designed to replicate the therapeutic effects of natural CBD without containing tetrahydrocannabinol (THC). For example, in January 2024, Akumentis Healthcare Ltd., an India-based pharmaceutical company, launched Clasepi, a synthetic cannabidiol (CBD) product approved by the Drug Controller General of India (DCGI). Clasepi is designed to treat seizures associated with conditions such as Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, and Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older. It is the first synthetic CBD product of its kind available in India, containing less than 0.1% THC, making it non-psychotropic. Clinical studies have shown that Clasepi is effective in reducing seizures, particularly in patients who have not responded to traditional antiseizure medications. Proper adherence to healthcare providers' instructions is critical for optimal use and safety.

In January 2022, Dermapharm Holding SE, a Germany-based healthcare company, acquired C3 Cannabinoid Compound Company GmbH for €80 million ($84.08 million). This acquisition helps Dermapharm strengthen its position in the growing cannabis market and expand its distribution channels in Europe, particularly in anticipation of cannabinoid therapy legalization and increasing acceptance. The acquisition also enhances Dermapharm's ability to develop and market both natural and synthetic cannabinoids, positioning the company for future growth in this expanding sector. C3 Cannabinoid Compound Company GmbH is based in Germany and specializes in the development, production, and marketing of both natural and synthetic cannabinoids.

Major players in the epidiolex (cannabidiol) market are Cannoid LLC, Jazz Pharmaceuticals Plc, Curaleaf Holdings Inc., Trulieve Cannabis Corp., Cresco Labs Inc., Tilray Brands Inc., Columbia Care Inc., Canopy Growth Corporation, Acreage Holdings Inc., Verano Holdings Corp., Aurora Cannabis Inc., Planet 13 Holdings Inc., The Cronos Group Inc., Folium Biosciences LLC, Green Roads of Florida LLC, Medterra CBD LLC, Endoca B.V., CV Sciences Inc., NuLeaf Naturals LLC, Isodiol International Inc., PharmaHemp d.o.o., Koi CBD LLC, Elixinol Global Limited, Vapen CBD LLC, and 180 Life Sciences Corp.

North America was the largest region in the epidiolex (cannabidiol) market in 2024. The regions covered in epidiolex (cannabidiol) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the epidiolex (cannabidiol) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The epidiolex (cannabidiol) market consists of sales of roasted cannabidiol gummies, vapes, tinctures and sleep aids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Epidiolex (Cannabidiol) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on epidiolex (cannabidiol) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for epidiolex (cannabidiol) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epidiolex (cannabidiol) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Oral Solution; Capsules; Oil Solution
• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 3) By Application: Epilepsy Treatment; Dravet Syndrome Treatment; Lennox-Gastaut Syndrome Treatment; Seizure Management
• Subsegments:
• 1) By Oral Solution: Standard Oral Solution; High-Concentration Oral Solution
• 2) By Capsules: Standard Capsules; Extended-Release Capsules
• 3) By Oil Solution: Standard Oil Solution; Concentrated Oil Solution
• Companies Mentioned: Cannoid LLC; Jazz Pharmaceuticals Plc; Curaleaf Holdings Inc.; Trulieve Cannabis Corp.; Cresco Labs Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Epidiolex (Cannabidiol) Market Characteristics

3. Epidiolex (Cannabidiol) Market Trends And Strategies

4. Epidiolex (Cannabidiol) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Epidiolex (Cannabidiol) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Epidiolex (Cannabidiol) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Epidiolex (Cannabidiol) Market Growth Rate Analysis
• 5.4. Global Epidiolex (Cannabidiol) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Epidiolex (Cannabidiol) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Epidiolex (Cannabidiol) Total Addressable Market (TAM)

6. Epidiolex (Cannabidiol) Market Segmentation

• 6.1. Global Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Solution
• Capsules
• Oil Solution
• 6.2. Global Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.3. Global Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epilepsy Treatment
• Dravet Syndrome Treatment
• Lennox-Gastaut Syndrome Treatment
• Seizure Management
• 6.4. Global Epidiolex (Cannabidiol) Market, Sub-Segmentation Of Oral Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Oral Solution
• High-Concentration Oral Solution
• 6.5. Global Epidiolex (Cannabidiol) Market, Sub-Segmentation Of Capsules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Capsules
• Extended-Release Capsules
• 6.6. Global Epidiolex (Cannabidiol) Market, Sub-Segmentation Of Oil Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Oil Solution
• Concentrated Oil Solution

7. Epidiolex (Cannabidiol) Market Regional And Country Analysis

• 7.1. Global Epidiolex (Cannabidiol) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Epidiolex (Cannabidiol) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Epidiolex (Cannabidiol) Market

• 8.1. Asia-Pacific Epidiolex (Cannabidiol) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Epidiolex (Cannabidiol) Market

• 9.1. China Epidiolex (Cannabidiol) Market Overview
• 9.2. China Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Epidiolex (Cannabidiol) Market

• 10.1. India Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Epidiolex (Cannabidiol) Market

• 11.1. Japan Epidiolex (Cannabidiol) Market Overview
• 11.2. Japan Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Epidiolex (Cannabidiol) Market

• 12.1. Australia Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Epidiolex (Cannabidiol) Market

• 13.1. Indonesia Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Epidiolex (Cannabidiol) Market

• 14.1. South Korea Epidiolex (Cannabidiol) Market Overview
• 14.2. South Korea Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Epidiolex (Cannabidiol) Market

• 15.1. Western Europe Epidiolex (Cannabidiol) Market Overview
• 15.2. Western Europe Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Epidiolex (Cannabidiol) Market

• 16.1. UK Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Epidiolex (Cannabidiol) Market

• 17.1. Germany Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Epidiolex (Cannabidiol) Market

• 18.1. France Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Epidiolex (Cannabidiol) Market

• 19.1. Italy Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Epidiolex (Cannabidiol) Market

• 20.1. Spain Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Epidiolex (Cannabidiol) Market

• 21.1. Eastern Europe Epidiolex (Cannabidiol) Market Overview
• 21.2. Eastern Europe Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Epidiolex (Cannabidiol) Market

• 22.1. Russia Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Epidiolex (Cannabidiol) Market

• 23.1. North America Epidiolex (Cannabidiol) Market Overview
• 23.2. North America Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Epidiolex (Cannabidiol) Market

• 24.1. USA Epidiolex (Cannabidiol) Market Overview
• 24.2. USA Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Epidiolex (Cannabidiol) Market

• 25.1. Canada Epidiolex (Cannabidiol) Market Overview
• 25.2. Canada Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Epidiolex (Cannabidiol) Market

• 26.1. South America Epidiolex (Cannabidiol) Market Overview
• 26.2. South America Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Epidiolex (Cannabidiol) Market

• 27.1. Brazil Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Epidiolex (Cannabidiol) Market

• 28.1. Middle East Epidiolex (Cannabidiol) Market Overview
• 28.2. Middle East Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Epidiolex (Cannabidiol) Market

• 29.1. Africa Epidiolex (Cannabidiol) Market Overview
• 29.2. Africa Epidiolex (Cannabidiol) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Epidiolex (Cannabidiol) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Epidiolex (Cannabidiol) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Epidiolex (Cannabidiol) Market Competitive Landscape And Company Profiles

• 30.1. Epidiolex (Cannabidiol) Market Competitive Landscape
• 30.2. Epidiolex (Cannabidiol) Market Company Profiles
  • 30.2.1. Cannoid LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Jazz Pharmaceuticals Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Curaleaf Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Trulieve Cannabis Corp. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Cresco Labs Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Epidiolex (Cannabidiol) Market Other Major And Innovative Companies

• 31.1. Tilray Brands Inc.
• 31.2. Columbia Care Inc.
• 31.3. Canopy Growth Corporation
• 31.4. Acreage Holdings Inc.
• 31.5. Verano Holdings Corp.
• 31.6. Aurora Cannabis Inc.
• 31.7. Planet 13 Holdings Inc.
• 31.8. The Cronos Group Inc.
• 31.9. Folium Biosciences LLC
• 31.10. Green Roads of Florida LLC
• 31.11. Medterra CBD LLC
• 31.12. Endoca B.V.
• 31.13. CV Sciences Inc.
• 31.14. NuLeaf Naturals LLC
• 31.15. Isodiol International Inc.

32. Global Epidiolex (Cannabidiol) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Epidiolex (Cannabidiol) Market

34. Recent Developments In The Epidiolex (Cannabidiol) Market

35. Epidiolex (Cannabidiol) Market High Potential Countries, Segments and Strategies

• 35.1 Epidiolex (Cannabidiol) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Epidiolex (Cannabidiol) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Epidiolex (Cannabidiol) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer